Introduction {#s1}
============

Effector differentiation of a naïve CD8^+^ T cell begins when its T cell receptor (TCR) recognizes a peptide-MHCI ligand complex. If the interaction is strong enough, a cascade of signalling events follows that allows the naïve T cell to differentiate and expand into a pool of effector cells. Signal transduction downstream of the TCR involves a highly diverse network of post-translational protein modifications that ultimately drive transcriptional, translational, metabolic and cytoskeletal changes in the cell. It is estimated that fewer than 0.01% of naïve CD8^+^ T cells can recognize a particular foreign peptide-MHCI complex ([@bib43]). Despite the diversity of rearranged TCRs on these naïve cells and the extensive range of antigenic peptides that may be presented, the intracellular machinery within each naïve T cell is able to sense the strength of the receptor-ligand interaction and mount an appropriate response.

Previous work has demonstrated that the strength of stimulation a T cell receives upon binding a peptide-MHC ligand complex determines its fate in the thymus and its probability of activating in the periphery. During thymic selection, T cells that weakly recognize self-peptides are retained, while those that strongly recognize self-peptides undergo negative selection and are removed ([@bib19]; [@bib34]; [@bib44]; [@bib77]). In the periphery, the population response to stimuli of different strengths can vary in speed, magnitude and phenotype ([@bib24]; [@bib48]; [@bib65]; [@bib71]; [@bib72]; [@bib107]). Work from our group and others indicates that these observations may be explained by the fact that stimulation strength controls the rate with which individual cells activate transcriptional and proliferative processes ([@bib35]; [@bib80]). This then raises the question, how does stimulation strength impact signalling downstream of the TCR, and how does this relate to transcriptional activation ([@bib8])?

Many previous studies have examined signalling mediators and their coordinated network during naïve T cell activation ([@bib46]; [@bib50]; [@bib99]). Signalling through the TCR ([@bib15]; [@bib68]) begins with LCK and Fyn-mediated tyrosine phosphorylation of ITAM motifs on the invariant CD3 subunits. This creates a high affinity binding site for ZAP70, which, upon phosphorylation and activation, leads to the generation of the LAT-SLP76 signalosome. From here, signalling activates multiple cascades including MAPK (MEK1/2-ERK1/2), PDK1-PI3K, calcium, and NFκB (including IκBα-p65) pathways, each amplified and propagated via a series of phosphorylation events or other post-translational modifications. Signal transduction pathways can be broadly categorized as digital, with distinct 'on' or 'off' outcomes, or analogue, giving rise to a graded response ([@bib14]; [@bib108]). In digital signalling, once the threshold for activation is surpassed, an output signal of constant intensity is produced. In analogue signalling, higher intensity of the originating stimulus results in a proportionally higher intensity of the output signal.

Previous work has demonstrated that ligand potency determines the extent of signalling at various proximal and distal nodes ([@bib72]; [@bib82]). Studies focused on digital signalling nodes showed that stimulation strength affects the percentage of cells that phosphorylate ERK ([@bib3]; [@bib20]; [@bib93]), PKD2 ([@bib67]), IκBα and the p65 component of NFκB ([@bib49]). Most of these studies have looked at each signalling molecule separately. It therefore remains unclear how ligand potency affects the coordination of signalling downstream of the TCR in naïve T cells.

TCR-induced responses are rapid and often transient, and responding cell populations can be heterogeneous. Single-cell approaches are therefore well-suited to examining this system. Mass cytometry provides single-cell resolution, uses antibody-mediated measurements that can detect post-translational signalling protein modifications, and can achieve high-dimensionality through simultaneous measurement of up to 40 epitopes ([@bib9]; [@bib10]; [@bib56]; [@bib70]). Previous mass cytometry studies of T cell signalling have demonstrated that small differences in proximal signalling molecules are propagated and amplified in downstream targets ([@bib63]) and that the interplay of 'activatory' versus 'inhibitory' signalling components determines the response of effector T cells to different antigen doses ([@bib101]).

In this study, we designed a mass cytometry panel probing surface receptors and elements of key signalling pathways ([Figure 1](#fig1){ref-type="fig"}) to examine the effect of stimulation strength on naïve CD8^+^ T cell responses. We used a minimal antigen presentation system to ask how modulating only the strength of the TCR-pMHC interaction affects signalling pathways without the influence of variable costimulatory factors or feedback from other cell types. Our multi-dimensional approach allowed us to determine how ligand potency impacts the synchronization of multiple parallel pathways. Through simultaneous measurement of S6 phosphorylation and early mRNA transcripts, we also examined the concurrent activation of these markers of translational and transcriptional processes. Our data suggest that the coordination of the TCR-induced signalling pathways that we tested does not vary with stimulation strength. Instead, strength of stimulation determines the rate with which T cells initiate this programme.

![Diagrammatic representation of TCR signalling pathways measured by mass cytometry panel.\
Cartoon depicts the TCR-related signalling pathways examined in this study in our minimal stimulation system wherein T cells present antigen to each other. Solid lines indicate evidence of direct and dotted lines suggested or indirect interaction. Signalling proteins and post-translational modifications directly measured by mass cytometry antibodies are coloured blue (proteins) or green/red (sites of phosphorylation events) and outlined in purple. The mass cytometry panel also profiled surface proteins TCRβ, CD8α, CD45, CD25 (IL2Rα), and CD44.](elife-53948-fig1){#fig1}

Results {#s2}
=======

Mass cytometry detects active T cell conjugates {#s2-1}
-----------------------------------------------

We used the OT-I TCR transgenic mouse on a recombination-activating gene (RAG)-deficient background as a model for evaluating the impact of stimulation strength on TCR signalling pathways. In this model, all peripheral CD8^+^ T cells recognize the ovalbumin peptide SIINFEKL. Variants of SIINFEKL with altered potency for the OT-I TCR allow manipulation of the strength of TCR stimulation ([@bib19]; [@bib34]; [@bib36]; [@bib82]). In this study, we used the high potency SIINFEKL (N4), intermediate potency SIITFEKL (T4), and low potency SIIGFEKL (G4) peptides, as well as an unrelated control peptide, ASNENMDAM (NP68).

We designed a custom mass cytometry antibody panel to detect five surface markers of T cell identity and activation, eight phosphorylated signalling proteins with corresponding total proteins, and IκBα, which is degraded in response to stimulation ([Figure 1](#fig1){ref-type="fig"}; Materials and methods). The antibodies labelled key components of major signalling pathways, including proximal signalling (pZAP70\[Y319\]/pSyk\[Y352\], pSLP76\[Y128\], pLCK\[Y505\] and pPLCγ1\[Y783\]), the MAPK pathway (pERK1/2\[T202/Y204\]), the PDK1-PI3K and mTOR pathways (pAKT\[S473\], pS6\[S235/S236\]), the NFκB pathway (IκBα) and the IL2 pathway (pSTAT5\[Y694\]). All of these phosphorylation sites indicate active signalling with the exception of the inhibitory Y505 phosphorylation of LCK ([@bib18]; [@bib61]). Measurement of total proteins allowed us to determine whether changes in phospho-protein staining were due to differences in signalling or protein expression levels.

We isolated naïve CD8^+^ T cells from OT-I *Rag1*^-/-^ splenocytes before stimulating with ligands of various strengths. To monitor signalling while naïve CD8^+^ T cells transitioned to activated T cells, and to relate signalling to changes in mRNA and protein expression during this process, cells were stimulated for 1, 2, 4 and 6 hr. We used a minimal, controlled system of peptide addition, allowing T cells to present antigens to each other. We also added exogenous IL2 to mitigate effects of potency-dependent differences in paracrine IL2 ([@bib6]; [@bib24]; [@bib60]; [@bib92]; [@bib96]; [@bib98]) and provide all cells with an effector-promoting environment ([@bib75]; [@bib96]). This system was chosen in order to examine the cell-intrinsic effects of TCR stimulation strength on signalling pathways. Peptides were added at 1 µM since peptide titration revealed minimal differences in the percentage of cells phosphorylating S6 and ERK between 100 nM and 1 µM stimulation conditions ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Using this reductionist stimulation system, we previously found that stimulation strength determined the rate with which naïve T cells initiated transcriptional activation but that cells activated by all ovalbumin-derived ligands were proliferating and expressing the effector molecule CD44 by two days ([@bib80]).

Stimulated cells were stained with metal-conjugated antibodies and markers for dead cells and DNA before profiling by mass cytometry. We gated events detected by the mass cytometer in a hierarchical manner to select single, living cells that were TCRβ^+^ and CD8α^+^ before examining individual signalling molecules ([Figure 2a](#fig2){ref-type="fig"}). While gating for single cells based on DNA content ([Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}), we noted that a substantial percentage of events contained more than one cell-equivalent of DNA, particularly among cells stimulated with the strongest peptide, N4 ([Figure 2---figure supplement 2b](#fig2s2){ref-type="fig"}). Separating events by DNA content revealed two distinct populations, such that events containing two cell-equivalents of DNA had higher phosphorylated and total protein staining ([Figure 2b](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2c--d](#fig2s2){ref-type="fig"}). It is therefore likely that this population contained multiple cells (i.e. doublets), potentially even cells engaged in TCR-peptide-MHC interactions with their neighbours. After normalization of each phosphorylated protein to the DNA signal detected in the same mass cytometry event, signal intensities for events with two cell-equivalents of DNA had similar ranges to those of events with one for most markers ([Figure 2---figure supplement 2e](#fig2s2){ref-type="fig"}). This provided further evidence that events with two cell-equivalents of DNA were doublets. Supporting the hypothesis that these doublets represented actively conjugated cells, a greater proportion of doublets than singlets showed signalling behaviour. In addition, from 1 to 4 hr after stimulation, pSLP76 signal was higher in doublet events even after normalization, suggesting that SLP76 was preferentially phosphorylated in cells actively engaged in TCR-peptide-MHC interactions. Because it was not possible to discern which proteins were signalling in which cell in a multiplet event, for subsequent analyses we included only singlet events.

![Mass cytometry measurements of signalling in singlet and doublet events.\
(**a**) Naïve CD8^+^ T cells were stimulated with 1 μM peptides of various potencies for 0, 1, 2, 4 and 6 hr before profiling by mass cytometry. Histograms depict pS6 signal. (**b**) Bubble plots of all signalling molecules after stimulation as in (**a**) in mass cytometry events with 1 or 2 cell-equivalents of DNA (singlets or doublets, respectively). The size of the bubbles denotes the percentage of positive cells, and the colour denotes the centred and scaled median intensity of each positive fraction. Results are representative of cells from six biological replicates measured in two independent experiments as detailed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.](elife-53948-fig2){#fig2}

Ligand potency affects the kinetics of signalling protein activation {#s2-2}
--------------------------------------------------------------------

We next examined the kinetics of individual signalling molecules within our mass cytometry data. Total levels of signalling proteins did not substantially change over a 6 hr stimulation, while expression of effector proteins CD44 and CD25 increased in a time- and potency-dependent manner ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In the presence of exogenous IL2, ligand potency did not strongly influence the rate with which individual cells phosphorylated STAT5 ([Figure 3---figure supplement 2a](#fig3s2){ref-type="fig"}). In the absence of exogenous IL2, STAT5 phosphorylation was associated with ligand potency, such that weak G4-stimulated cells showed no STAT5 phosphorylation ([Figure 3---figure supplement 2b](#fig3s2){ref-type="fig"}), likely due to autocrine/paracrine IL2 rapidly secreted by strongly stimulated cells ([@bib92]). The percentages of cells degrading IκBα or phosphorylating S6 or ERK1/2 were not impacted by the presence of exogenous IL2. The percentages of cells phosphorylating pAKT\[S473\] were subtly increased by IL2 particularly under stimulation with low potency ligands ([Figure 3---figure supplement 2b](#fig3s2){ref-type="fig"}). This may reflect the mechanism proposed by Ross et al. whereby JAK signalling induced by IL2 ultimately stimulates mTORC2 phosphorylation of AKT\[S473\] ([@bib83]). Together, these data indicate the selectivity of IL2 effects on T cell signalling pathways.

Phosphorylation of proximal, membrane-recruited mediators ZAP70 and PLCγ1 was only detectable in a small percentage of cells at any point during this time course, preventing further interpretation ([Figure 2b](#fig2){ref-type="fig"}). For LCK, the percentage of cells with inhibitory phosphorylation of pY505 decreased at 6 hr in a potency-dependent manner, suggesting that stronger stimuli resulted in greater LCK activity only at this late time point ([Figure 3---figure supplement 2a](#fig3s2){ref-type="fig"}). For SLP76, the high potency ligand N4 induced a greater percentage of signalling cells and greater signalling intensity within these cells between 1 and 4 hr, whereas signalling was minimal in cells stimulated with intermediate (T4) or low potency (G4) ligands ([Figure 2b](#fig2){ref-type="fig"}, [Figure 3---figure supplement 2a](#fig3s2){ref-type="fig"}).

Examination of the kinetics of individual distal signalling molecules revealed two distinct patterns. We defined these as transient if the percentage of signalling cells increased and subsequently decreased during the time course of high potency stimulation, and sustained if maximal signalling was ongoing at 6 hr ([Figure 3a](#fig3){ref-type="fig"}). ERK1/2, AKT and IκBα displayed transient signalling. While ERK1/2 and AKT are phosphorylated in response to TCR stimulation, IκBα is degraded, releasing NFκB subunits and permitting their translocation to the nucleus ([@bib73]). Therefore, a reduction in IκBα^+^ cells indicates active signalling by this node. For these three signalling mediators, the percentage of cells actively signalling was maximal at 2 hr when stimulated with the highest potency N4 peptide but was delayed until 4 or 6 hr when stimulated with the lower potency T4 or G4 peptides ([Figure 3a](#fig3){ref-type="fig"}). After 2 hr, signalling via these proteins declined in strongly stimulated cells, resulting in a convergence with more weakly stimulated cells. In addition, the maximum percentage of cells signalling through these nodes was substantially higher in strongly stimulated cells. This may indicate repeated node activation after high potency stimulation, such that a greater proportion of cells were signalling at any given time of measurement. Thus, for these transiently signalling proteins, ligand potency was associated with the maximal proportion of signalling cells and the speed with which this proportion was reached on a populational level.

![Kinetics of selected signalling proteins and impact of MEK and mTOR pathway inhibitors on T cell activation parameters.\
(**a**) The percentage of cells positive for each marker is plotted against time. Results depict combined data from six biological replicates measured in two independent experiments as detailed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Points represent the mean and error bars depict the SD. Data underlying plots are provided in [Supplementary file 5](#supp5){ref-type="supplementary-material"}. (**b--c**) Flow cytometry measurements of pS6\[S235/236\] and pERK1/2 after 2 hr of pre-treatment with DMSO vehicle control, rapamycin (Rapa) 200 nM, MEK162 (MEK) 0.5 μM, 1 μM and 5 μM, or combined rapamycin with MEK162 (R + M), followed by 4 hr stimulation with 1 μM N4 or NP68 peptides. Results are representative of 3 independent experiments. (**d**) The fraction of pS6^+^ cells in N4-stimulated conditions with the indicated inhibitor treatments versus DMSO (top). The median fluorescent intensity of pS6 among pS6^+^ cells in N4-stimulated conditions with the indicated inhibitor treatments (bottom). Lines represent the median. Results depict combined data from three independent experiments.](elife-53948-fig3){#fig3}

In contrast to these transient signalling events, S6 phosphorylation induced by TCR stimulation was sustained within our time course ([Figure 3a](#fig3){ref-type="fig"}). Under N4 stimulation, there was a rapid initial increase in the percentage of pS6^+^ cells before a plateau. This pattern may be indicative of the signalling protein approaching saturation. The appearance of pS6^+^ cells was slower after stimulation with lower potency ligands, but the proportions of pS6^+^ cells approached convergence between N4, T4 and G4 stimulations at 6 hr. Thus, for S6, the rate with which cells exhibited active signalling, but not the maximal proportion of signalling cells was associated with ligand potency.

We observed a bimodal distribution of pERK1/2 measurements in our mass cytometry data, consistent with previous reports ([@bib3]; [@bib20]; [@bib93]). The extent of ERK1/2 phosphorylation in pERK1/2^+^ cells, as determined by the median marker intensity, was unaffected by ligand potency ([Figure 3---figure supplement 3a](#fig3s3){ref-type="fig"}). This confirmed that ERK1/2 exhibits digital signalling behaviour, that is on a per cell basis there is either an 'on' or 'off' state. Similarly, pS6\[S235/S236\] signal was also bimodally distributed ([Figure 2a](#fig2){ref-type="fig"}, [Figure 3---figure supplement 3b](#fig3s3){ref-type="fig"}). The intensity of pS6 signal in pS6^+^ cells slightly increased over time. Normalization to total S6 protein intensity mitigated this effect (particularly under strong stimulation) and suggested that ligand potency may subtly affect the rate of S6 phosphorylation within individual cells ([Figure 3---figure supplement 3c](#fig3s3){ref-type="fig"}) in addition to the percentage of pS6^+^ cells at early time points.

Since S6 phosphorylation at S235/S236 is driven by both S6K1 downstream of mTORC1, and RSK downstream of MEK1/2-ERK1/2 ([@bib74]; [@bib84]; [@bib86]), we were interested in how each of these pathways contributed to its digital behaviour in strongly stimulated cells. To this end, we treated cells with inhibitors of MEK1/2 (MEK162, [@bib52]) and mTOR (rapamycin, [@bib76]) before stimulation with N4 peptides ([Figure 3---figure supplement 3d](#fig3s3){ref-type="fig"}). The per-cell phosphorylation of S6 decreased moderately in response to rapamycin ([Figure 3b--c](#fig3){ref-type="fig"}), with little difference between doses of 20 nM and 2 μM ([Figure 3---figure supplement 3e](#fig3s3){ref-type="fig"}), but the bimodal distribution of pS6 and the percentage of pS6^+^ cells were not disturbed. In contrast, while S6 phosphorylation also decreased within each cell in response to MEK162, this response was dose-dependent between 0.5 and 5 μM, and at the highest dose (5 μM), the bimodality was disturbed. In addition, even low doses of MEK162 halved the percentage of cells with phosphorylated S6 ([Figure 3d](#fig3){ref-type="fig"}). Combined MEK162 and rapamycin resulted in severe inhibition of S6 phosphorylation ([Figure 3b](#fig3){ref-type="fig"}). Neither MEK162, rapamycin, nor the combination of these two substantially impacted CD44 expression at the concentrations of inhibitors used ([Figure 3---figure supplement 3f](#fig3s3){ref-type="fig"}), but a synergistic inhibition of cellular proliferation was observed after 2 days ([Figure 3---figure supplement 3g](#fig3s3){ref-type="fig"}). Thus, simultaneous activity of the MEK and mTOR pathways is required for phosphorylating S6\[S235/S236\] and proliferative responses, and MEK signalling is essential for S6 digital phosphorylation. These data emphasize the coordinated nature of signalling downstream of the TCR.

Ligand potency determines the abundance of signalling cells but not the coordination of signalling events {#s2-3}
---------------------------------------------------------------------------------------------------------

To take advantage of the simultaneous measurements in mass cytometry data, we next tested for differential abundance of multidimensional cellular phenotypes, taking into account all of the signalling markers measured ([@bib58]; [Figure 4a](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We first defined 1585 fine-grained phenotypic states in the high dimensional space. We then compared the abundance of cells within these phenotypic states between unstimulated and all stimulated conditions (Materials and methods). Clustering of significantly differentially abundant states revealed two main signalling phenotypes. Phenotype A, defined as pS6^+^ pSTAT5^+^ pERK1/2^+^, was most prevalent in the high potency (N4)-stimulated cells. Phenotype B, defined as pS6^+^ pSTAT5^+^ pERK1/2^-^, appeared under all stimulation conditions with similar prevalence ([Figure 4a](#fig4){ref-type="fig"}). Phenotypes A and B were paralleled by the pSTAT5^-^ phenotypes A' and B', respectively. Phenotypes A and A' were transient, whereas phenotypes B and B' were sustained. Subpopulation analysis confirmed that the high potency ligand N4 was capable of inducing a greater abundance of phenotypes A' (pS6^+^ pSTAT5^-^ pERK1/2^+^) and A (pS6^+^ pSTAT5^+^ pERK1/2^+^) up to 4 hr after stimulation ([Figure 4b](#fig4){ref-type="fig"}). In contrast, abundances of phenotypes B (pS6^+^ pSTAT5^+^ pERK1/2^-^) and B' (pS6^+^ pSTAT5^-^ pERK1/2^-^) increased at a similar rate between 1 and 6 hr after stimulation with all ovalbumin-derived ligands and were not associated with ordered ligand potency.

![Examination of multi-dimensional phenotypes in mass cytometry signalling data.\
(**a**) Mass cytometry stimulation time courses were further investigated for multidimensional phenotypes that changed in abundance with stimulation. Analysis was run on two multiplexed biological replicates as described in Materials and methods. Phenotypic hyperspheres were defined within the multidimensional mass cytometry space and abundances of cells from each condition enumerated within each hypersphere. Each column in the heatmap represents an individual hypersphere. At the top of the heatmap, rows correspond to mass cytometry marker measurements with colour depicting the intensity of each marker in each hypersphere. Clustering by Pearson correlation was performed on these hypersphere marker intensity measurements. At the bottom of the heatmap, rows correspond to stimulation conditions with colour depicting the binned log~2~-fold change in cellular abundance in stimulated versus unstimulated conditions within each hypersphere. ns = hyperspheres that did not significantly change in abundance. Phenotypic clusters of interest, A, A', B, B', are indicated in both CD44^+^ and CD44^-^ populations by coloured highlighting of the dendrogram. Statistics underlying the heatmap are provided in [Supplementary file 5](#supp5){ref-type="supplementary-material"}. (**b**) Percentages of cells exhibiting A, A', B, and B' phenotypes in mass cytometry measurements. Results are combined data from six biological replicates measured in two independent experiments as detailed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Points represent the mean and error bars depict the SD. Data underlying plots are provided in [Supplementary file 5](#supp5){ref-type="supplementary-material"}. (**c**) Phenotypes as in (**b**) further sub-divided by CD44 expression.](elife-53948-fig4){#fig4}

To complement these signalling phenotypes, we further investigated their relationship with surface expression of the effector protein CD44, which was an important contributor to phenotypic cluster separation ([Figure 4a](#fig4){ref-type="fig"}). We examined the 16 (2^4^) possible states defined by combinations of the markers CD44, pS6, pSTAT5 and pERK1/2. The strongest peptide, N4, was capable of inducing a large proportion of CD44^-^ pS6^+^ pSTAT5^-^ pERK^+^ cells after 1 hr of stimulation ([Figure 4c](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). This was accompanied by an increasing population of CD44^-^ pS6^+^ pSTAT5^+^ pERK^+^ cells, which reached its maximum abundance 2 hr after stimulation. Cells stimulated by the weaker peptides T4 and G4 showed dramatically reduced abundances of these cellular phenotypes, and their maxima were delayed. For all stimuli, a high abundance of CD44^-^ pS6^+^ pSTAT5^+/-^ pERK1/2^-^ cells was seen between 4 and 6 hr. Cells expressed CD44 by 4 hr after strong and intermediate stimulation (N4 and T4) and by 6 hr after weak stimulation (G4).

From these data, we inferred the coordination of distal TCR-induced signalling. We propose that within our stimulation system, activating cells initially phosphorylate S6 and ERK1/2, followed by STAT5, after which ERK1/2 becomes dephosphorylated, followed by STAT5 in some cells. In the early hours after stimulation, signalling cells express CD44 at the same level as unstimulated cells but begin upregulating CD44 expression by 4--6 hr. As time progresses and cells shift to sustained phenotypes, those activated with reduced potency ligands begin to phenotypically resemble those stimulated with high potency ligand ([Figure 5](#fig5){ref-type="fig"}). To formally test this order of activation events, we constructed activation trajectories of cells under each stimulation condition across all time points, based on their expression of pS6 ([Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}). We then asked in what order along these trajectories pS6, pERK1/2, pSTAT5, and CD44 activation events were initiated ([Figure 5---figure supplement 1b--c](#fig5s1){ref-type="fig"}). We found that pS6 appeared first, followed by pERK1/2, pSTAT5, and finally CD44. Of note, the start of ERK1/2 phosphorylation corresponded to the most dramatic increase in S6 phosphorylation, supporting evidence that ERK activation drives full S6\[S235/S236\] phosphorylation ([Figure 3](#fig3){ref-type="fig"}). The order of activation events was shared across stimulation conditions (p=0.00174 compared to random orders of events, Materials and methods). The signalling molecules pAKT, pLCK and IκBα were less dynamic along the trajectory, precluding precise determination of their order of activation particularly in weakly stimulated cells, but visualizing their changes along the trajectory further suggested shared patterns between stimuli ([Figure 5---figure supplement 1d](#fig5s1){ref-type="fig"}).

![Cartoon Model.\
Cartoon depicts the kinetics of the four main signalling phenotypes in cells stimulated with ligands of varying potencies (N4, T4, G4) over time from data in [Figures 3a](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} (note the transient pERK^+^ populations, even with G4). Black outlines indicate CD44^+^ populations.](elife-53948-fig5){#fig5}

We therefore conclude that ligand potency controls the rate with which cells achieve certain signalling states and that the order of these signalling events is preserved regardless of stimulation strength.

Biosynthetic pathways are coordinately regulated downstream of TCR activation {#s2-4}
-----------------------------------------------------------------------------

Finally, we shifted our focus further downstream to examine the relationship between signalling at the ribosomal protein S6 and mRNA expression of early response transcription factors. These two activation events indicate initiation of translational and transcriptional processes, which are required for the biosynthetic programs of T cell activation ([@bib5]; [@bib37]; [@bib92]). S6 is a ribosomal protein whose phosphorylation reflects, though it does not regulate, TCR-induced translation ([@bib88]; [@bib86]). *Nr4a1* (Nur77) and *Irf8* encode transcription factors that are rapidly expressed upon T cell activation ([@bib64]; [@bib69]), and we previously found that their transcripts are upregulated at 1 and 3 hr, respectively, after strong N4 stimulation ([@bib80]; [Figure 6---figure supplement 1a](#fig6s1){ref-type="fig"}). To examine these translational and transcriptional characteristics simultaneously, we activated naïve OT-I CD8^+^ T cells with ligands of various potencies before measurement of pS6 and mRNA molecules using combined phosphoflow and RNA flow cytometry ([Figure 6a](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"}).

![Simultaneous measurement of phosphorylation of S6 and mRNA expression of transcription factors Nr4a1 and Irf8.\
(**a**) Combined phosphoflow cytometry of pS6 and RNA flow cytometry of *Nr4a1* and *Irf8* transcripts in naïve OT-I CD8^+^ T cells stimulated with N4, T4, G4 or NP68 peptides for 2 hr, gated on single live cells in which the control gene *Rpl39* was detected. (**b**) Frequency of phenotypes depicted in (**a**) after stimulation for 1, 2, 4 or 6 hr. Data are representative of 3 independent experiments.](elife-53948-fig6){#fig6}

Stimulation time courses with the different potency ligands suggested that *Nr4a1* transcripts were upregulated before phosphorylation of S6 and downregulated after, while *Irf8* transcripts were upregulated after S6 phosphorylation ([Figure 6b](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1c](#fig6s1){ref-type="fig"}). This order of events appeared consistent across stimuli. The percentage of pS6^+^*Nr4a1^+^* cells was maximal between 1 and 2 hr after stimulation with the highest potency peptide N4, after 4 hr stimulation with the intermediate potency peptide T4, and after 6 hr stimulation with the lowest potency peptide G4. Likewise, the percentage of pS6^+^*Irf8^+^* cells was maximal after 2 hr stimulation with N4, 4 hr stimulation with T4 and 6 hr stimulation with G4 peptides ([Figure 6b](#fig6){ref-type="fig"}). Similar to the multi-dimensional signalling phenotypes we measured by mass cytometry, these altered kinetics of phosphorylation and transcript upregulation indicate that stimulation strength controls their rate of activation.

These results suggest that the relationship between signalling events is conserved under different strengths of stimulation, even among the differing signal transduction pathways controlling transcription and translation. Upon TCR activation both the transcriptional and translational machinery are deployed in a coordinated manner, which may improve efficiency of protein production enabling the naïve CD8^+^ T cell to differentiate and proliferate.

Ligand potency affects the kinetics of selected signalling proteins in the presence of professional antigen-presenting cells {#s2-5}
----------------------------------------------------------------------------------------------------------------------------

The interaction of adhesion molecules LFA-1 and ICAM-1 assists the formation of a stable immunological synapse, augments TCR-induced signalling, and continues to promote differentiation even after initial activation ([@bib29]; [@bib97]). LFA-1 is constitutively expressed by naïve T cells, and TCR stimulation drives both redistribution and conformational changes that enhance its binding to the ligand ICAM-1 ([@bib11]; [@bib26]; [@bib97]). Palmer et al. previously demonstrated that LFA-1-ICAM-1 interactions improve conjugate formation during T cell stimulation with peptide-loaded splenocytes, particularly for low potency ligands ([@bib72]). However, it remained unclear whether ICAM-1 was expressed in our stimulation system and whether this integrin interaction could thereby play a role. We therefore measured ICAM-1 on the surface of T cells 6 hr after addition of pure peptides of various potencies ([Figure 7---figure supplement 1a](#fig7s1){ref-type="fig"}) and found that all T cells expressed ICAM-1, regardless of their stimulation status. These data suggest that integrin adhesion likely contributes to T cell activation along with TCR stimulation and exogenous IL2 in our system.

In contrast to this reductionist system, many additional factors impact T cell activation in vivo. Most fundamentally, naïve T cells are activated in the lymph node by professional antigen-presenting cells (APCs), such as dendritic cells, instead of other T cells. These APCs express costimulatory ligands in addition to peptide-MHC complexes, which can further tune naïve T cell responses ([@bib13]; [@bib39]). For example, in our stimulation system, the costimulatory ligand CD80 remained largely absent after 6 hr of stimulation ([Figure 7---figure supplement 1a](#fig7s1){ref-type="fig"}). In contrast, mature bone marrow-derived dendritic cells (BMDCs) expressed high levels of CD80, along with additional costimulatory molecules ([Figure 7---figure supplement 1b--c](#fig7s1){ref-type="fig"}). To test how signalling responses to ligands of different strengths might be impacted by the additional signalling conferred by professional APCs, we stimulated naïve T cells with mature BMDCs loaded with peptides of various potencies. Exogenous IL2 was included to maintain comparability with the T:T stimulation system. Signalling molecules pZAP70, pSLP76, pERK1/2, pS6 and pSTAT5, as well as CD44 expression, were measured by flow cytometry.

We found that activation was in general less strong in the presence of peptide-pulsed professional APCs than pure peptides ([Figure 7](#fig7){ref-type="fig"}), perhaps due to reduced ligand availability as only half of the cells in the culture carried ligand (Materials and methods). The potency-dependent kinetics of pERK1/2, pSLP76 and CD44 resembled those observed in the T:T stimulation system, while pZAP70 remained undetectable. pS6 was upregulated over time under stimulation with high, medium and low potency ligands. pSTAT5 was upregulated over time with all stimuli, including the null peptide NP68, suggesting that simply mixing naïve T cells with BMDCs enhanced IL2 signalling. These results indicate that the rate-based mechanism we observed in the T:T stimulation system is further tuned at particular signalling nodes by more complex antigen presentation.

![Signalling phenotypes in T cells stimulated with peptide-pulsed APCs.\
(**a**) Naïve CD8^+^ T cells were stimulated with mature BMDCs loaded with peptides of various potencies for 1, 2, 4 and 6 hr before profiling by flow cytometry. The percentage of cells positive for each marker is plotted against time. Results depict combined data from three independent experiments. Points represent the mean and error bars depict the SD. (**b**) Example flow cytometry data from (**a**) of pERK1/2 and pS6 measured at 1 and 6 hr.\
Figure 7---source data 1.Data underlying plots in [Figure 7a](#fig7){ref-type="fig"}.](elife-53948-fig7){#fig7}

Discussion {#s3}
==========

In this study, we examined the coordination of signalling pathways downstream of TCR activation using a custom mass cytometry panel as well as protein and RNA flow cytometry. The use of multidimensional measurements allowed us to probe the simultaneous activation of multiple signalling and transcriptional processes. This enabled comparisons of the impact of ligand potency on not only individual activation events but also their coordination. We found that the strength of TCR stimulation controlled the rate of appearance of the multi-dimensional signalling and transcriptional phenotypes that we profiled.

Stimulation strength altering the rate of T cell activation has been observed in previous studies from our group and others investigating transcriptomic, proliferation, and protein characteristics ([@bib35]; [@bib80]; [@bib82]). Taken together, these data suggest that by controlling the probability that a cell will initiate activation responses, signal strength can modulate the average speed and magnitude of a population response. Our signalling results indicate that if such an activation switch exists, it lies very proximal to the TCR.

An important outstanding question is the mechanism by which the TCR translates ligand strength into the probability of downstream signalling. One model explaining the threshold for T cell response that could propagate to a rate-based mechanism is kinetic proofreading ([@bib62]). This theory postulates that the ligand must remain bound to the receptor for sufficient time for signalling accumulation to surpass a critical event and propagate downstream. Indeed, multiple reports have suggested that naïve T cells require sustained interaction with presented antigen to achieve optimal proliferation, though the necessary duration differs by study and likely depends on the presence of additional factors such as IL2 ([@bib7]; [@bib16]; [@bib41]; [@bib45]; [@bib78]; [@bib95]; [@bib94]; [@bib102]). Refinements to the kinetic proofreading model suggest that not a single interaction but rather the cumulative interaction lifetime of a series of early binding events controls signal accumulation ([@bib25]; [@bib54]). Biophysical investigations of the impact of force on binding events between the TCR and pMHC (as well as CD8) have described catch bonds formed with high potency ligands that extend interaction lifetimes ([@bib21]; [@bib36]; [@bib54]; [@bib91]; [@bib104]), though this observation has not been universal ([@bib53]) and merits further investigation. Extrapolating from this lifetime theory, altered ligand potency could change the probability of long or rapidly repeated binding events, thereby controlling the probability that an individual cell activates.

If such a lifetime-based mechanism exists, T cells must then translate variation in binding lifetime to the presence or absence of downstream signalling. Palmer and colleagues found ligand potency-associated differences in CD3ζ chain and ZAP70 phosphorylation ([@bib19]; [@bib72]), which may allow potency-dependent accumulation of signal before propagation downstream. Supporting this hypothesis, John James demonstrated that the number of CD3 ITAM motifs in a synthetic receptor influenced the rate but not the magnitude of signalling within individual Jurkat cells ([@bib42]). Likewise, Mukhopadhyay et al. found that the presence of multiple ζ chain ITAMs, as well as ZAP70, increases the efficiency of phosphorylation in a HEK 293T cell reconstitution system, although these phosphorylation events do not account for the apparent switch-like ultrasensitive behaviour of T cell signalling ([@bib66]). One mechanism that could explain the switch-like behaviour is the zero-order ultrasensitivity model ([@bib28]; [@bib30]), wherein negative regulators act in combination with activators to enhance responsiveness when signalling molecules operate close to saturation. In this way, a relatively small change in the binding lifetime of a pMHC ligand could be amplified by altering a kinase/phosphatase ratio to switch between the presence and absence of downstream signalling. An alteration in the local relative abundances of phosphatase CD45 and kinase LCK described by the kinetic segregation model ([@bib22]; [@bib79]) represents an intriguing candidate for controlling a zero-order ultrasensitivity mechanism ([@bib40]), although a subsequent study has refuted its requirement for T cell activation ([@bib1]), suggesting other mechanisms. Control may also be mediated by the phosphatase PTPN22, which can dephosphorylate CD3ζ chains, ZAP70 and LCK ([@bib103]), as absence of PTPN22 results in increased proportions of activated cells, particularly under weak stimulation ([@bib87]). Alternatively, Lo et al. showed that the slow phosphorylation of a tyrosine residue in LAT is a possible candidate for this rate-limiting step, since substitution of a single residue that enhances this phosphorylation improves T cell response to low potency ligands ([@bib55]).

Through our single-cell measurements, we confirmed ([@bib3]; [@bib20]; [@bib93]) that ERK1/2 is phosphorylated with 'on or off' states, characteristic of digital signalling. In addition, we found that S6\[S235/S236\] is also phosphorylated in a similar manner. However, whilst the extent of ERK1/2 phosphorylation during the 'on' state was constant, the extent of S6 phosphorylation subtly increased both with time and strength of stimulus. The parallel subtle increase in total S6 expression over time implies induction of S6 protein production during T cell activation. These data suggest that dividing signalling proteins into digital or analogue can be complicated by changes in total protein levels that may attribute analogue properties to a digital signal.

Previous work has shown that in addition to mTORC1 signalling, the MEK/ERK pathway contributes to S6\[S235/S236\] phosphorylation ([@bib74]; [@bib84]), particularly in naïve T cells ([@bib50]). Therefore, combinatorial effects of mTORC1 and MEK signalling might be expected to influence both S6 phosphorylation and other downstream T cell activation phenotypes. We found that chemical inhibition of both of these pathways blocked S6 phosphorylation, implying that they contribute in a non-redundant manner. A dose titration with MEK162 indicated that MEK/ERK signalling is critical for phosphorylation of S6\[S235/S236\]. Even at low doses, MEK162 reduced the percentage of pS6^+^ cells, suggesting that it may modulate the rate of response. Furthermore, in our trajectory analysis of multiple signalling markers, a steep increase in S6 phosphorylation coincided with the appearance of pERK^+^ cells under all peptide stimuli ([Figure 5---figure supplement 1a--b](#fig5s1){ref-type="fig"}). These data raise the possibility that digital phosphorylation of ERK propagates through RSK to S6\[S235/S236\].

We additionally explored the effects of rapamycin and MEK162 on naïve T cell proliferation. Although rapamycin had little effect on S6 phosphorylation, it had a profound effect on T cell proliferation, which may be due to several different mechanisms. First, rapamycin can also impact mTORC2 signalling after prolonged treatment ([@bib90]), and naïve T cells may be particularly susceptible ([@bib23]). Second, mTORC1 affects many additional pathways other than ribosomal activity ([@bib76]; [@bib89]). Finally, even when signalling through S6K1, mTORC1 can influence proliferation through pS6-independent mechanisms ([@bib88]). We also found that MEK inhibition with MEK162 synergized with rapamycin to further dampen T cell proliferation, highlighting the interconnected nature of the signalling pathways downstream of the TCR.

Many signalling molecules exhibited transient behaviour at the population level (ERK1/2, IκBα, AKT), while pS6 accumulated over the course of our 6 hr experiments. Stimulation strength strongly influenced the proportion of cells exhibiting transient signalling behaviours between 1 and 4 hr after activation, but by 6 hr, cells activated with any of the ovalbumin-derived peptide ligands exhibited a similar signalling phenotype. This potency-dependent difference in the maximal proportions of cells signalling may be due to either repeat or sustained signalling with strong ligands, the latter of which has been observed for calcium fluxes induced by TCR stimulation ([@bib12]; [@bib51]; [@bib105]). For example, although under weak G4 stimulation only a very small percentage (15.4%) of cells were found to be pERK1/2^+^ at any given time, the majority (72.1%) of G4-stimulated cells achieved digital activation of pS6\[S235/236\] by 6 hr ([Figure 3a](#fig3){ref-type="fig"}). Given that we found full S6 phosphorylation after strong stimulation requires MEK signalling, we hypothesize that this pathway is active in all stimulation conditions but that ERK activation events occur with reduced frequency or duration with weak stimuli and thus many were missed in our snapshot measurements. Future investigations using ERK reporters and ERK inhibition in weakly stimulated cells would be needed to test this prediction. Consistent with this proposed mechanism, single-cell studies in epithelial and HEK293 cell lines have observed oscillating ERK phosphorylation with frequency and duration dependent on the concentration or frequency of EGF stimulation ([@bib2]; [@bib85]). Such an effect on digital ERK activation may be modulated by multi-step activation of the upstream mediator SOS dependent on its dwell-time after activation-induced recruitment to the plasma membrane ([@bib38]). Interestingly, using a light-inducible ERK activation system in epithelial cells, Aoki et al. demonstrated divergent transcriptional effects of sustained versus transient ERK activation ([@bib4]). It therefore remains possible that different ERK targets in T cells, such as translational machinery, microtubule remodelling, and transcription factors (e.g. ELK1, SAP1, SAP2) ([@bib68]) are differentially affected by stimulation strength, warranting further investigation of additional downstream components.

Examination of the coordinated activation of transcriptional and translational signalling pathways also revealed conservation of this order of events. Biosynthetic processes are critical for naïve T cells to differentiate into effector cells ([@bib5]; [@bib92]), and thus, carefully controlled simultaneous activation would ensure efficient, consistent effector differentiation of activated cells.

Under stimulation with peptide-loaded BMDCs, ligand potency determined the percentages of T cells undergoing certain activation events (pERK1/2, pSLP76 and CD44), similar to observations in our reductionist stimulation system. In contrast, phosphorylation of S6 was not associated with ligand potency after stimulation with peptide-loaded BMDCs. Unlike naïve and recently activated T cells, BMDCs express high levels of costimulatory molecules that can impact TCR-induced signalling. For example, ligation of the costimulatory receptor CD28 at the same time as the TCR results in amplification of signalling pathways including NFAT, NFκB and AP-1, and can enhance both the sensitivity and ultimate division potential of naïve T cell activation ([@bib27]; [@bib33]; [@bib60]; [@bib106]). Further exploration of how individual costimulatory ligands impact the coordination and initiation rate of the TCR-induced signalling programme will be important for dissecting these additional inputs.

Despite the increased complexity of BMDC peptide presentation, this in vitro system is nevertheless still far-removed from in vivo T cell activation, where the microenvironment is increasingly complex. Additional variables such as cytokine and nutrient availability and cell-cell interactions can further tune the T cell response in vivo ([@bib17]; [@bib47]). Moreover, strongly stimulated T cells undergo prolonged retention in the lymph node ([@bib71]; [@bib107]) and may out-compete weakly stimulated T cells for cytokines and nutrients ([@bib100]), suggesting that stimulation strength and the microenvironment are not independent. Our controlled in vitro systems allowed us to identify effects of stimulation strength on TCR-induced pathways alone, as well as in the context of BMDC-mediated costimulation, without confounding by other in vivo factors and feedback. By delineating the impact of stimulation strength in low-complexity systems, these data can form the basis for interpretation of future studies where additional variables may be explored.

In this study, we measured 22 markers of protein expression and active signalling. While other unmeasured signalling mediators may respond to altered stimulation strength in a different manner, our data demonstrate a strict choreography of the distal signalling processes that we examined. Stimulation strength was associated with the rate with which cells embarked on this regimented programme. This suggests that using a limited set of signalling machinery in a single coordinated programme, T cells can finely tune their responses to different ligands through modulation of the rate of signalling.

Materials and methods {#s4}
=====================

Key resources {#s4-1}
-------------

Key resources are detailed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Mice {#s4-2}
----

CD8^+^ T cells were isolated from OT-I *Rag1*-deficient mice (OT-I *Rag1*^tm1Bal^ on a C57BL/6 background), which underwent confirmation of genotype prior to study. BMDCs were generated from wild-type C57BL/6 mice. Experiments used both male and female mice 9--25 weeks old. Mice were bred and maintained within University of Cambridge animal facilities.

Cell culture and stimulation {#s4-3}
----------------------------

For T cell isolation, single cell suspensions of splenocytes were produced via homogenization of the spleen through a 70 µM nylon strainer. CD8^+^ T cells were isolated using the Mouse CD8α^+^ T cell Isolation Kit (MACS Miltenyi Biotec). Cells were cultured in RPMI 1640 (Gibco), 10% FBS (Biosera), penicillin-streptomycin (Sigma), sodium pyruvate (Gibco), L-glutamine (Sigma), β-mercaptoethanol (Gibco) and 20 ng/ml recombinant mouse IL-2 (Peprotech). For stimulation, the following peptides were used at the concentrations indicated: SIINFEKL (N4), SIITFEKL (T4), SIIGFEKL (G4), and ASNENMDAM (NP68) (Cambridge Bioscience).

Bone marrow derived dendritic cells (BMDCs) were generated based on a published protocol by Abcam. Femurs and tibias were sterilized in 70% ethanol and flushed with cold BMDC culture media, consisting of RPMI 1640 (Gibco), 10% FBS (Biosera), penicillin-streptomycin (Sigma), L-glutamine (Sigma) and β-mercaptoethanol (Gibco). The suspension of bone marrow progenitor cells was passed through a 70 µM nylon strainer and plated in 10 cm petri dishes in BMDC culture media supplemented with 20 ng/ml GM-CSF (Peprotech). Fresh BMDC culture media with 20 ng/ml GM-CSF was added on day three and replaced on day six and, if needed, day 8. Immature dendritic cells were harvested from day 7 to day 9. Maturation was induced by culturing immature dendritic cells for 1 day in BMDC culture media with 20 ng/ml GM-CSF, as well as 50 ng/ml LPS (Thermofisher Scientific) and 20 ng/ml IL4 (Abcam). Differentiation into immature and mature BMDCs was verified by flow cytometry. To stimulate T cells, mature BMDCs were pulsed with 1 µM of peptide for 1 hr at 37°C, washed, mixed with naïve T cells at a ratio of 1:1, and cultured for the times indicated.

Mass cytometry {#s4-4}
--------------

Purified naïve CD8^+^ T cells were analysed by mass cytometry. In experiment 1, cells from four age-matched mice (two males and two females) were used, representing four biological replicates. In experiment 2, more stimulation conditions were included. This necessitated more cells for each biological replicate than could be obtained from a single mouse. Therefore, each biological replicate (one male, one female) was composed of cells from a pair of age- and gender-matched mice. Staining for mass cytometry was performed using sequential MaxPar reagent kits (Fluidigm) in the following steps. Live cells were stained with 5 µM Cell-ID Cisplatin for 5 min at 37°C and rested for 15--30 min before stimulation with 1 µM N4, T4, G4, or NP68 peptides, or left unstimulated. In Experiment 1, cells were stimulated for 1 and 2 hr. In experiment 2, cells were stimulated for 1, 2, 4 and 6 hr. See [Supplementary file 1](#supp1){ref-type="supplementary-material"} for replicate structure. Cells were fixed with Maxpar Fix I Buffer for 10 min at room temperature. Cells stimulated under different conditions were barcoded using the Cell-ID 20-Plex Pd Barcoding Kit and pooled for staining to minimise confounding technical differences. In experiment 1, all cells from each mouse were pooled into a batch. In experiment 2, in addition to pooling within a biological replicate, four samples were shared across the two pools to enable batch normalization for differential abundance analysis as described below. Cells were blocked with FCR blocking reagent (Biolegend, clone 93) and stained with metal-conjugated surface antibodies ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). Surface-stained cells were permeabilized with methanol (Fisher Scientific) and stained with metal-conjugated antibodies against intracellular targets ([Supplementary file 3](#supp3){ref-type="supplementary-material"}), all diluted in Maxpar Cell Staining Buffer. Stained cells were then fixed with 1.6% formaldehyde (Thermofisher) and stained overnight with 125 nM Cell-ID Intercalator-Ir in Maxpar Fix and Perm Buffer. Cells were analysed on a Helios CyTOF system (Fluidigm). Data within each cell pool were normalized and debarcoded using the Fluidigm CyTOF software.

Mass cytometry antibodies {#s4-5}
-------------------------

Metal-conjugated antibodies were custom-conjugated where not already commercially available ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). All custom-conjugated antibody clones were tested using phosphoflow cytometry before and after metal-conjugation. When allocating metals to antibody targets, brighter metals were assigned to antibodies that exhibited weaker phosphoflow staining or to those without clear bimodal expression. Metal channels that receive significant cross-over from other channels were also allocated antibodies with stronger signals. For each protein target, antibodies against the total protein and its phosphorylated version were conjugated to metals differing by more than one mass unit to avoid spillover.

Antibodies targeting phosphorylated proteins were validated using phosphoflow (with and without metal conjugation) under different stimulating conditions, including anti-CD3 coated plate (1 µg/ml, BD Biosciences, clone 145--2 C11), PMA (50 nM, Sigma-Aldrich) and ionomycin (1 µg/ml, Sigma-Aldrich), N4 peptide (1 µM), and pervanadate (1 mM, prepared using sodium orthovanadate, Sigma-Aldrich) ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). To confirm the specificity of the antibody clones targeting ZAP70, LCK and SLP76, we transfected HEK 293 T cells, which lack endogenous expression of these proteins, with vectors encoding the proteins and tested antibody binding via flow cytometry and immunofluorescence ([Supplementary file 4a](#supp4){ref-type="supplementary-material"}). To confirm the specificity of the antibody clone targeting PLCγ1 (3H1C10), we performed siRNA knockdown in T cells and tested antibody binding by flow cytometry ([Supplementary file 4a](#supp4){ref-type="supplementary-material"}). (Knockdown was validated by western blotting with a WB-specific antibody clone (D9H10).) Further validation of phospho-specific antibodies was performed using signalling inhibitors as detailed in the antibody specificity tables ([Supplementary file 4](#supp4){ref-type="supplementary-material"}).

All metal-conjugated antibodies were tested by mass cytometry prior to experimentation. By testing antibodies on fixed cells, fixed and barcoded cells, and live cells (surface markers only), we confirmed there was no additional loss of antibody activity through the addition of the barcoding step. Two surface markers performed less well when fixed (CD62L-160Gd clone MEL-14 and CD69-143Nd clone H1.2F3, both Fluidigm). The CD62L-160Gd antibody was excluded from the mass cytometry panel. The CD69-143Nd antibody was excluded from the analyses in experiment 1, and excluded from the staining panel in experiment 2. All metal-conjugated antibodies were titrated for optimal performance and key signalling antibodies were tested in a time-course assay under different stimulatory conditions to determine the optimal times for running the full panel.

Mass cytometry data analysis {#s4-6}
----------------------------

For mass cytometry analysis in FlowJo (v10), debarcoded samples were gated in a hierarchical manner: EQ bead exclusion followed by selection of intact cells based on DNA content, single cells based on the event length and DNA content, living cells based on cisplatin staining, and finally CD8α^+^ TCRβ^+^ cells. For activation-induced markers, positive/negative status was defined based on comparison with unstimulated cells.

Normalization of antibody-measured signals to DNA signal, as well as phospho-protein to total protein signals, was performed in R using the ncdfFlow (v2.30.1) ([@bib31]) and flowCore (v1.50.0) ([@bib32]) Bioconductor packages. The signal of each marker in each event was normalized to the signal from the 191Ir DNA channel or appropriate total protein channel within that event. Normalized ratios were then scaled to the median 191Ir DNA or appropriate total protein signal from one selected sample for visualization purposes.

To test for differential abundances, mass cytometry data from experiment 2 was processed using the ncdfFlow (v2.30.1), flowCore (v.1.50.0) and cydar (v1.8.0) ([@bib58]) Bioconductor Packages in R. A logicle transformation (default parameters except w = 0.1) was applied to raw intensity data. Data from the two batches were range-normalized based on the four samples that were included in both batches using the normalizeBatch function (with parameters p=0.001, fix.zero = TRUE). After normalization, one technical replicate from each of these four repeated samples was carried forward for analysis. All samples were then pooled before constructing the sequential gating strategy: removal of residual EQ beads, removal of events with high event length, retaining events with a single cell-equivalent of DNA, removal of dead cells, removal of cells with TCRβ signal more than 5 MAD below the median, and removal of cells with CD8 signal more than 5 MAD below the median. Cells from each sample were down-sampled to the number in the smallest sample (10,982). Only signalling proteins and selected surface markers were included in differential abundance testing (to avoid invariant and non-biological markers): pSTAT5, pAKT, pSLP76, pLCK, IκBα, pPLCγ1, pERK1/2, pZAP70, pS6, CD8α, CD44, CD25, TCRβ, CD45.

To test for differential abundance of cells with any combinatorial phenotype, agnostic to cellular density or clustering patterns, we employed cytometry differential abundance testing in R (cydar, [@bib58]). This method takes advantage of the consistent staining achieved with sample barcoding, along with the count-based nature of single cell data, to find regions of the high-dimensional marker space occupied significantly more or less frequently by cells from a particular condition. This is achieved by filling the marker space with hyperspheres, comparing cellular abundances within each hypersphere across conditions, and controlling the false discovery rate across the marker space. Cells were assigned to hyperspheres and counted using the prepareCellData, neighborDistances, and countCells functions from cydar (default parameters except countCells tol = 0.4 and downsample = 200). Hyperspheres were included in differential abundance analysis if they contained more than 50 cells on average. Differential abundance was assessed using the edgeR (v3.26.8) Bioconductor package ([@bib57]; [@bib81]) with a robust quasi-likelihood GLM fit ([@bib58]) including the biological replicate of origin as a blocking factor for each sample in an analysis of deviance test to identify hyperspheres that changed in abundance in any stimulation condition compared to the unstimulated control. The spatial FDR was controlled at 0.05 to define significantly differentially abundant hyperspheres. See [Supplementary file 5](#supp5){ref-type="supplementary-material"} for full summary statistics from differential abundance testing.

For trajectory analysis, each biological replicate was analysed separately. A logicle transformation (default parameters except w = 0.1) was applied to raw intensity data. Cells within each replicate were then gated using the sequential strategy described above. The MAD threshold for TCRβ^+^ cells was relaxed in gating biological replicates from experiment 1 due to a wider distribution in this dataset. To construct trajectories, equal numbers of cells stimulated by each ovalbumin-derived ligand were pooled with unstimulated cells. This created one sample per ligand (N4, T4 and G4) per biological replicate from which to construct trajectories. For each trajectory, cells were ordered by intensity of pS6 as this marker was observed to increase with activation over real time. Colouring cells by real time point confirmed enrichment of cells sampled at early times at the beginning of the trajectory and later times at the end ([Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}). To generate plots in [Figure 5---figure supplement 1b--c](#fig5s1){ref-type="fig"}, a loess curve was fitted to intensity measurements of the indicated markers across 2000 randomly sampled cells from each trajectory (span = 0.2). To determine the trajectory interval in which each activation event started, trajectories were downsampled to 5000 cells each, and a sliding window encompassing 5% of the trajectory was established to move across the trajectory from least to most activated in steps of 1%. The first window in which the mean intensity of cells was more than one standard deviation away from the mean intensity in the starting window was deemed the initiation of the activation event. Events that displayed a shift in mean intensity across the trajectory but fell short of the threshold (CD44 under G4 stimulation), were considered to be last in the ordering. If more than one activation event failed to meet this threshold in a given trajectory, or if two events shared an initiation window, it was not possible to robustly declare the order. We then computed the probability that orders of signalling events would be shared between each pair of trajectories to the observed extent or more if orders were random. To do this, we compared the mean-squared-distance (MSD) between the orders in trajectory 1 and trajectory 2 to a distribution of MSDs between the orders in trajectory 1 and permuted orderings of trajectory 2. Both biological replicates from experiment 2 that contained all time-points revealed identical orders of activation events across all stimulation conditions. The two biological replicates in experiment 1 that included 0, 1 and 2 hr of stimulation also revealed the same order of activation of pS6 and pERK, while pSTAT5 and CD44 were not sufficiently activated by 2 hr to determine their ordering. It was not possible to order events in the remaining biological replicates from experiment one that included only one stimulated timepoint.

Flow cytometry {#s4-7}
--------------

To test BMDC maturation, cells were stained with live-dead marker (Zombie-NIR or Zombie-Aqua Fixable Viability Kit, Biolegend) in PBS before staining in incubation buffer (1% FBS in PBS) with FCR (FC receptor) blocking antibody (Biolegend, clone 93) and antibodies against CD11c, MHC II, CD80, CD86, CD40 and ICAM1 ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Cells were acquired on a BD LSRFortessa. Data were analysed in FlowJo (v10) gating on single, live cells. Mature BMDCs were consistently \>90% CD11c^+^ and MHC II^+^ ([Figure 7---figure supplement 1b](#fig7s1){ref-type="fig"}). To measure CD80 and ICAM-1 expression on activated T cells, T cells were stained with live-dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) and antibodies against CD80 and ICAM1 in the same way.

To test the impact of inhibiting the MEK and mTOR pathways on cell proliferation ([Figure 3---figure supplement 3g](#fig3s3){ref-type="fig"}), cells were stained with eBioscience Cell Proliferation Dye eFluor-450 (ThermoFisher), pre-treated for 2 hr with MEK162 (1 µM and 5 µM), rapamycin (200 nM) or combined MEK162 (1 µM or 5 µM) and rapamycin (200 nM), and stimulated with 1 µM N4 or NP68 peptides for 2 days. Cells were then stained with live-dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) and acquired on a BD LSRFortessa. Data were analysed in FlowJo (v10) gating on live, single cells.

Phosphoflow cytometry {#s4-8}
---------------------

For phosphoflow cytometry experiments in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 3b--d](#fig3){ref-type="fig"}, [Figure 3---figure supplements 2b](#fig3s2){ref-type="fig"} and [3d--g](#fig3s3){ref-type="fig"}, and [Figure 7](#fig7){ref-type="fig"}, after stimulation, cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) at room temperature for 15 min and washed in PBS. Cells were permeabilized with 90% ice-cold methanol (Fisher Scientific) for 30 min on ice or overnight at −20°C. Cells were washed in PBS and resuspended in 100 µL incubation buffer containing FCR blocking antibody (Biolegend, clone 93), stained with the primary antibodies of interest ([Supplementary file 2](#supp2){ref-type="supplementary-material"}), and incubated for 1 hr at room temperature. In cases where the primary antibody was not conjugated to a fluorophore, the cells were then washed, resuspended in 100 µL incubation buffer containing FCR blocking antibody and secondary antibody ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) and incubated for 30 min at room temperature. Cells were washed in incubation buffer prior to data acquisition on a BD LSRFortessa. Data were analysed in FlowJo (v10) gating on single, live cells.

To test the impact of titrating peptides on the phosphorylation of ERK and S6 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), cells stained with live-dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) were stimulated with N4, T4, G4 and NP68 peptides at concentrations of 10 nM, 100 nM and 1 µM for 2 and 4 hr.

To test the impact of adding or withholding exogenous IL2 on phosphorylation of STAT5, S6, ERK, and AKT, and degradation of IκBα ([Figure 3---figure supplement 2b](#fig3s2){ref-type="fig"}), cells stained with a live-dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) were stimulated with 1 µM of peptides for 4 hr.

To test the impact of inhibiting the MEK/ERK and mTOR/S6 pathways ([Figure 3b--d](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3d-f](#fig3s3){ref-type="fig"}), cells stained with live-dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) were pre-treated with the MEK inhibitor MEK162 (binimetinib/ARRY-162/ARRY-438162, Selleckchem), mTOR inhibitor rapamycin (Sigma-Aldrich) or combined MEK162 and rapamycin for 2 hr. MEK162 was added at 0.5 µM, 1 µM and 5 µM, rapamycin was added at 20 nM, 200 nM and 2 µM. For combined drug treatments, MEK162 was added at 0.5 µM, 1 µM and 5 µM with rapamycin at 200 nM. DMSO as a vehicle control was added at 1:1000, corresponding to the amount in the 200 nM dose of rapamycin and the 1 µM dose of MEK162. Cells were stimulated with 1 µM of N4 or NP68 peptides for 4 hr.

To test naïve T cell stimulation with peptide-loaded BMDCs, T cells were stained with live-dead marker (Zombie-NIR Fixable Viability Kit, Biolegend) before co-culture with BMDCs.

Combined phosphoflow with RNA flow cytometry {#s4-9}
--------------------------------------------

To combine phosphoflow with RNA flow cytometry ([Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1b-c](#fig6s1){ref-type="fig"}), purified naïve CD8α^+^ T cells were stained using a live-dead marker (Zombie Aqua Fixable Viability Kit, Biolegend). To achieve a sufficient number of cells, isolated naïve CD8^+^ T cells from three age- and gender-matched mice were pooled for each biological replicate. Cells were stimulated for 0--6 hr with 1 µM N4, T4, G4, or NP68 peptides. At the end of stimulation, cells were immediately moved on to ice and washed with cold PBS. Cells were fixed and permeabilized using the Primeflow RNA Assay Kit (ThermoFisher Scientific), blocked with FCR blocking reagent (Biolegend, clone 93) and stained with antibodies against pS6\[S235/236\] (BD Biosciences clone N7-548) for 30 min. Cells were stained with the following PrimeFlow probe sets (Thermofisher Scientific): *Nr4a1* AF647 (Type1, VB1-12484-204), *Irf8* AF750 (Type 6, VB6-3197312-210), and *Rpl39* AF488 (Type 4, VB4-3120826-204) as a control. The use of *Rpl39* as a control gene was previously described in naïve and recently activated CD8^+^ T cells ([@bib80]). Cells were acquired on a BD LSRForessa and analysed in FlowJo (v10). Cells were gated on single, live cells that expressed *Rpl39,* to ensure cells were permeabilized and probes hybridized and amplified.

Code availability statement {#s4-10}
---------------------------

Analysis code for mass cytometry data is available at <https://github.com/MarioniLab/SignallingMassCytoStimStrength> ([@bib59]; copy archived at <https://github.com/elifesciences-publications/SignallingMassCytoStimStrength/>).
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###### Antibody testing and specificity.

Antibody specificity tables detail experiments used to test and validate (a) antibodies targeting total proteins and (b-c) signalling proteins. Tables also include relevant references utilising these clones in knockout, knockdown, overexpression or small molecule inhibitor experiments.

###### Mass cytometry figure underlying data.

Tables provide means and standard deviations of kinetics curves depicted in [Figures 3a](#fig3){ref-type="fig"} and [4b--c](#fig4){ref-type="fig"}, and [Figure 3---figure supplement 2a](#fig3s2){ref-type="fig"}, as well as summary statistics from hypersphere differential abundance testing depicted in [Figure 4a](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.

Data availability {#s7}
=================

Raw mass cytometry data can be found on the Flow Repository, accession numbers FR-FCM-Z2CX and FR-FCM-Z2CP. Full results of mass cytometry analyses are included as Supplementary File 5. Source data for summary plots of flow cytometry-measured signaling markers in T cells stimulated with peptide-loaded BMDCs (Figure 7a) are included as Figure 7 - Source Data File 1. Analysis code is available at <https://github.com/MarioniLab/SignallingMassCytoStimStrength> (copy archived at <https://github.com/elifesciences-publications/SignallingMassCytoStimStrength>).

The following datasets were generated:

MaCYMarioniJCGriffithsGMRichardAC2019Ma et al CD8+ T cell signalling panel experiment 2Flow RepositoryFR-FCM-Z2CP

MaCYMarioniJCGriffithsGMRichardAC2019Ma et al CD8+ T cell signalling panel experiment 1Flow RepositoryFR-FCM-Z2CX
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

You have generated a highly detailed and powerful in vitro analysis of T cell signaling networks triggered by a range of peptide-MHC potencies. The finding that responses to weak ligands activate similar signalling pathways, but with different kinetics, adds to our understanding of how CD8^+^ T cells cope with the wide range of ligand potencies that are encountered physiologically. We also appreciate that you have acknowledged the potential of the Erk1/2 node to encode qualitatively distinct responses to ligand of differing potency, which may also be an important observation for going forward.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"TCR stimulation strength controls the rate of initiation but not the molecular organization of signalling\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Michael L Dustin as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Christoph Wuelfing (Reviewer \#2).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

Your study illustrates the great potential of multiplexing to analyse outputs of multiple signaling pathways using mass cytometry and you present an interesting hypothesis that ligands of different potencies control kinetics, rather than the nature of signals generated. The weaknesses of the study include lack of information about the outcome of this mode of T cell activation, potential gaps in coverage of relevant signaling pathways that could reveal differences with ligand potency, and circumstantial evidence for the final working model. It was felt that addressing these concerns in 2 months was not possible.

Reviewer \#1:

The authors have performed stimulation of OTI T cells in vitro using \"self\" presentation of peptides introduced into the media for 1-6 hrs followed by mass cytometry or flow cytometry based analysis of signaling proteins, their phospho-forms and selected surface markers and mRNAs. The authors conclude that there are no major differences in the activation of the signaling nodes by the different potency ligands, but only difference in the rate and extent of activation of the same network. This result extends recent results from the same group on single cell transcriptomics that also showed the same gene expression trajectories with different potencies of peptides for OT1 TCR under similar in vitro stimulation conditions. The study is carefully performed generating a data set with two biological replicates from a transgenic mouse model that is expected to have limited variability. Despite the enormous complexity of the dataset, two major clusters A and B and be tracked and appear to occur in the responding cells for all potencies of peptides, but faster and to a great extent for more potent peptides.

1\) The schematic in Figure 1 depicts a signaling network down down-stream of T cell interaction with an APC. If I correctly understand the system, the pMHC are being presented by naïve T cells, which express limited CD80 basally, although this may be induced during the 6 hr and this may change differentially with the peptides. The authors should include CD80 and ICAM-1 among the surface markers (perhaps by flow cytometry) to understand other aspects of signal evolution over the first 6 hrs though increased co-stimulation and adhesion. Some details in this figure may un-necessarily add to the complexity- for example- Y192 on Lck doesn\'t really come into the study and inspection of the data in the paper suggests that while phosphorylation at this site can generate negative feedback, the conditions under which this would happen is not clear and the conditions are unlikely to come into play in the very simple conditions in this paper. I think this figure could be simplified for focus on relevant information, in addition to providing an accurate picture of the experiment that is done- with another T cell as the APC.

2\) The authors note that the highest potency peptide induce significant numbers of events in the mass cytometry with 2x DNA. This seems likely to be biologically relevant conjugate formation related to the self-presentation of the pMHC between T cells, which is the only form of antigen presentation in the system. These events are not further analyzed, it would be helpful to have a global analysis of the % of these events for each time point with each peptide as the loss of these events may skew the analysis as the cells engaged in conjugates may be the most highly activated cells, for example, with higher levels of ICAM-1 and CD80 driving stronger conjugate formation. It's possible that the progression to particularly stable LFA-1 dependent conjugates during T cell activation may also be a relevant phenotype for T cell differentiation as suggested by work from Gerard and colleagues (Gerard A, Khan O, Beemiller P, Oswald E, Hu J, Matloubian M, Krummel MF. Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8^+^ T cells. Nat Immunol. 2013;14(4):356-63.).

3\) The study has limitations in that it focuses on a very simplified antigen presentation process that very much emphasizes the TCR-pMHC interaction in the context of a T-T interaction, which is not the way T cell priming would work. In the CD8 system the major differentiation process relates to whether or how terminal effector and long-lived memory cells are generated. It seems unlikely that T-T presentation would generate any T cell memory so this aspect of terminal differentiation vs generation of cells with stem cell line characteristics, and if this would be impacted by ligand potency, is not addressed. In the bigger picture of CD8 T cell biology some acknowledgement of these issues and how one might bridge these studies to address that issues would be helpful to readers.

4\) With only two biological replicates there is a question of statistical significance of the observations. Can the authors comment on the reproducibility of the mass cytometry experiment? Is there a way to attach a statistical likelihood to the possibility that the signaling trajectories are actually different for the different ligands, but this has been missed due to variability of the data and the limited number of replicates? This is an interesting cased where there is a lot of very detailed data from only two observations (plus additional flow cytometry data sets) and there is effectively only one technical replicate as I believe the two biological replicates were run at the same time on the machine with bar coding to distinguish them. Some discussion of how statistical assessment of the conclusion can be made would be very helpful.

Reviewer \#2:

Understanding the complexity of T cell signalling requires information-rich data. Mass cytometry with large panels of antibodies against signalling intermediates and their active states is a powerful method to provide such data. Its application to naïve T cell activation is highly welcome. Ma et al. applied an antibody panel determining activity of nine components of the T cell signalling system to the activation of naïve MHC I-restricted T cell receptor transgenic T cells in response to peptides with a range of affinities by having T cells present MHC/peptide complexes to each other at time points between one and six hours. Differential activation of three of the signalling intermediates, Erk, STAT5 and S6, allowed for distinction between different T cell activation conditions such that frequency and/or dynamics of the activation of these signalling intermediates vary. The manuscript powerfully illustrates the potential of mass cytometry to unravel complex mechanisms in T cell signalling. However, a modest scale and a few experimental constraints substantially limit the actual insight gained into T cell activation.

In this manuscript, naïve T cells are activated by presenting peptide to each other. I appreciate that this allows for the unambiguous assignment of mass cytometry signals to the T cells. It also forces T cells to activate with limited availability of costimulation. This may explain why there is virtually no activation of four (fairly proximal) of the nine signalling intermediates assayed, ZAP-70, SLP-76, PLCgamma and Akt. There are no changes in Lck phosphorylation (consistent with Acuto lab data) and CD25 expression. Thus, the nine signalling intermediate panel essentially contracts to four signalling intermediates, Erk, STAT5, S6 and IκB. This removes a key strength of mass cytometry from this study, the ability to determine relations between significant changes across numerous events. Some signalling intermediates are preferentially expressed in T cells, e.g. LAT and SLP-76. They, therefore, could be unambiguously detected in T cells activated more efficiently by professional APCs such as dendritic cells. In addition, as mass cytometry is a single cell approach, T cells could be dissociated from activating APCs before processing for mass cytometry and T cell-specific events identified with antibodies against T cell surface markers, such as the TCR or CD8. Even though a complete study using professional APCs such as DCs would be well beyond the scope of any revision, any insight from pilot experiments whether such APCs could trigger more effective signalling that can be unambiguously be assigned to the T cells would be of great use for other investigators planning to use mass cytometry to investigate T cell signalling.

The authors decided to supply exogenous IL-2. As IL-2 provides auto/paracrine amplification of T cell activation this likely has led to less variable data sets. However, increased distinction between T cell activation conditions provided by such amplification could have also provided additional physiological insight into mechanisms of T cell signal discrimination. Again, some initial insight from pilot studies that would extend the determination of the role of exogenous IL-2 from STAT5 and SP6 to other signalling intermediates could be of great value to other investigators.

One of the key challenges in T cell signalling is to connect signalling on the time scale of minutes to hours to cell fate on the time scale of days. While there is plenty of data in general on the response of naïve OT-I T cells to the peptide variants used , e.g. in the induction of proliferation, cytokine secretion and cytolytic capability, it would be good if such data directly related to the specific naïve T cell activation conditions used here, i.e. peptide presentation between naïve T cells. This is of particular interest as signalling differences at the last, 6-hour, time point in response to the different peptides are surprisingly small (as beautifully summarised in Figure 4---figure supplement 2 and also apparent in Figure 6B). This raises important questions. With signalling differences at 6 hours that small, what are the consequences for presumably substantially divergent later activation events? If later differences are more closely related to signalling at 2 to 4 hours, how are such differences "remembered"? Do we need to find additional signalling events to effectively link signalling on the time scale of hours to consequences on the time scale of days? Thus, knowing standard T cell activation outcomes in response to the different peptides under the specific experimental T cell activation conditions used in this study would be very useful.

In summary, the manuscript powerfully illustrates how much and interesting data can in principle be generated by applying mass cytometry approaches to T cell activation. In its current form, however, physiological insight remains limited by the small effective size of the antibody panel (only three discriminatory markers), the choice of T cell activation without APC and upon addition of exogenous IL-2 and the lack of direct relation to long-term outcomes of T cell signalling under the chosen experimental conditions. An expansion of the antibody panel is certainly beyond the scope of any reasonable revision. However, pilot experiments to illustrate consequences of the experimental choices together with a determination of long-term T cell activation consequences and an acknowledgement of limitations in physiological insight caused by the small effective antibody panel could still make this an influential manuscript for future work on unravelling T cell signalling complexity with mass cytometry.

Reviewer \#3:

Ma at al. used the CyTof technology to determine in parallel and with single cell resolution several molecules that are involved in TCR signal transduction. They used this approach with the intention to gain new insights into how different qualities of TCR ligation (high versus low affinity) translate into different T cell responses.

This is in principle a highly relevant and in key parts still barely understood matter. However, I have several issues with the manuscript of which the key points are i) lack of novelty and ii) that only circumstantial evidence is presented.

I see only incremental new insights that in my opinion do not move the field forward or provide real answers. Moreover, the authors want to put the message forward that mainly kinetic difference and not the signals quality determine the outcome of high versus low affinity signaling. While this is an interesting hypothesis, the authors present only circumstantial evidence and do not establish a causal relationship.

Other issues involve that the authors mainly use a fixed concentration of peptide which is with 1uM quite high, while titration experiments are rare. Moreover, would the same signaling pattern be observed when the cells are exposed to the same ligands in vivo?

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"Stimulation strength controls the rate of initiation but not the molecular organization of TCR-induced signalling\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Aleksandra Walczak as the Senior Editor The following individuals involved in review of your submission have agreed to reveal their identity: Christoph Wuelfing (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus, the revisions requested below only address clarity and presentation.

Your paper provides extremely detailed study of the kinetics of different activation responses in individual CD8 T cells triggered by TCR ligands with a well-defined hierarchy of affinities. You have also been very responsive to the comments of the reviewers in the first round, clarifying the statistical strength of their experimental design and adding key experiments in response to reviewer comments.

The reviewers and editors nonetheless suggest essential revision to address the potential of pErk1/2 to encode information about the different ligands that may not be fully read out in your otherwise thorough analysis. One effect that stands out in the data appears to be an affinity-related all-or- none involvement of the ERK pathway. Activation or lack of activation of pERK distinguishes two clusters of otherwise-coordinate responses, and while this pERK activation is frequent and early in cells activated by high-affinity ligands, it is hardly detectable at all in cells activated with low-affinity ligands, even at later time-points when all the other pathways have become activated. The fact that all the other pathways tested show kinetic but not qualitative differences in response to high and low affinity ligands makes the distinctive behavior of ERK very interesting.

You state that: \"Given that we found full S6 phosphorylation requires MEK signalling, we hypothesize that transient ERK activation events (Ryu et al., 2018) occurred in many cells outside of the snapshots of our measurements.\" You assume that if you used a \"real-time\" reporter that G4 would cause pErk1/2 to \"blink\" at a frequency sufficient to account for the Mek contribution of pS6, but very rarely captured in the snapshot? It might be helpful to be more explicit about this or even make this prediction if it's how you account for the result. It seems that what we know about pErk activation could fit with this and in addition to Ryo et al. it might make sense to cite Huang WYC, Alvarez S, Kondo Y, Lee YK, Chung JK, Lam HYM, Biswas KH, Kuriyan J, Groves JT. A molecular assembly phase transition and kinetic proofreading modulate Ras activation by SOS. Science. 2019;363(6431):1098-103. Epub 2019/03/09. doi: 10.1126/science.aau5721. PubMed PMID: 30846600; PMCID: PMC6563836 as it makes a case for how Erk activation down stream of Sos could have this property. Is it possible that even though this blinking is sufficient for pS6, that perhaps other TF like Elk might decode this differently and allow qualitatively different responses to these ligands? While the Erk1/2 signal may be showing such blinking, this is not demonstrated here and the pS6 phosphorylation could be driven by other signals than Erk1/2. Figure 5 is actually misleading in the absence of direct evidence for the pErk in the G4 cells. This requires a more critical discussion as it's not clear you have proven that the cell will ignore the information encoded in the pERK1/2 node even if your untested working model is correct.

10.7554/eLife.53948.sa2

Author response

\[Editors' note: The authors appealed the original decision. What follows is the authors' response to the first round of review.\]

> Reviewer \#1:
>
> 1\) The schematic in Figure 1 depicts a signaling network down down-stream of T cell interaction with an APC. If I correctly understand the system, the pMHC are being presented by naïve T cells, which express limited CD80 basally, although this may be induced during the 6 hr and this may change differentially with the peptides. The authors should include CD80 and ICAM-1 among the surface markers (perhaps by flow cytometry) to understand other aspects of signal evolution over the first 6 hrs though increased co-stimulation and adhesion.

We have now measured CD80 and ICAM-1 on the surface of naïve T cells after 6 hours of stimulation with strong, medium, weak or null ligands (new Figure 7---figure supplement 1A). These results demonstrate that ICAM-1 expression is unchanged between stimuli and CD80 expression is absent. As the ICAM-1 ligand LFA-1 is expressed by naïve T cells, ICAM-1-LFA-1 interactions may therefore play a role in the stimulation system we used, but CD80-CD28 co-stimulation is unlikely to. For comparison with professional antigen-presenting cells, we examined the same molecules on the surface of BMDCs (new Figure 7---figure supplement 1B), which were found to express high levels of both CD80 and ICAM-1. These results and their implications are now described in the text as follows:

"The interaction of adhesion molecules LFA-1 and ICAM-1 assists the formation of a stable immunological synapse, augments TCR-induced signalling, and continues to promote differentiation even after initial activation (Gérard et al., 2013; Verma and Kelleher, 2017). \[...\] In contrast, mature bone marrow-derived dendritic cells (BMDCs) expressed high levels of CD80, along with additional costimulatory molecules (Figure 7---figure supplement 1B)."

> Some details in this figure may un-necessarily add to the complexity- for example- Y192 on Lck doesn\'t really come into the study and inspection of the data in the paper suggests that while phosphorylation at this site can generate negative feedback, the conditions under which this would happen is not clear and the conditions are unlikely to come into play in the very simple conditions in this paper. I think this figure could be simplified for focus on relevant information, in addition to providing an accurate picture of the experiment that is done- with another T cell as the APC.

We have modified Figure 1 to depict only the signalling pathways we measured and more directly model the systems we investigated.

> 2\) The authors note that the highest potency peptide induce significant numbers of events in the mass cytometry with 2x DNA. This seems likely to be biologically relevant conjugate formation related to the self-presentation of the pMHC between T cells, which is the only form of antigen presentation in the system. These events are not further analyzed, it would be helpful to have a global analysis of the % of these events for each time point with each peptide as the loss of these events may skew the analysis as the cells engaged in conjugates may be the most highly activated cells, for example, with higher levels of ICAM-1 and CD80 driving stronger conjugate formation. It's possible that the progression to particularly stable LFA-1 dependent conjugates during T cell activation may also be a relevant phenotype for T cell differentiation as suggested by work from Gerard and colleagues (Gerard A, Khan O, Beemiller P, Oswald E, Hu J, Matloubian M, Krummel MF. Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8^+^ T cells. Nat Immunol. 2013;14(4):356-63.).

We have added new Figure 2---figure supplement 2B to show the percentage of doublet events across conditions.

We thank the reviewer for pointing out the findings of Gerard et al. The critical differentiation period Gerard et al. identified occurs roughly 24 hours after stimulation when T-T synapses allow cytokine exchange. While highly relevant for subsequent differentiation, this process is likely too late to examine in the short stimulation time courses we ran. Instead of we have added text to highlight the importance of LFA-1-ICAM-1 interactions, including a citation of this role identified by Gerard et al. (as described in response to point 1).

> 3\) The study has limitations in that it focuses on a very simplified antigen presentation process that very much emphasizes the TCR-pMHC interaction in the context of a T-T interaction, which is not the way T cell priming would work. In the CD8 system the major differentiation process relates to whether or how terminal effector and long-lived memory cells are generated. It seems unlikely that T-T presentation would generate any T cell memory so this aspect of terminal differentiation vs generation of cells with stem cell line characteristics, and if this would be impacted by ligand potency, is not addressed. In the bigger picture of CD8 T cell biology some acknowledgement of these issues and how one might bridge these studies to address that issues would be helpful to readers.

We agree that our in vitro system is skewed toward effector differentiation but believe that there are advantages to using such a reductionist system to investigate the impact of signal strength. By minimizing inputs from co-stimulation, we were able to ask how modulating *only* the strength of the TCR-pMHC interaction affects signalling pathways. We have clarified the inherent effector bias of this culture system as follows:

"We used a minimal, controlled system of peptide addition, allowing T cells to present antigens to each other. We also added exogenous IL2 to mitigate effects of potency-dependent differences in paracrine IL2 (Au-Yeung et al., 2017; Denton et al., 2011; Marchingo et al., 2014; Tan et al., 2017; Verdeil, Puthier, Nguyen, Schmitt-Verhulst, and Auphan-Anezin, 2006; Guillaume Voisinne et al., 2015) and provide all cells with an effector-promoting environment (Pipkin et al., 2010; Verdeil et al., 2006). This system was chosen in order to examine the cell-intrinsic effects of TCR stimulation strength on signalling pathways."

We have also added new data examining naïve T cells stimulated by peptide-loaded BMDCs (new Figure 7, as described in response to reviewer 2 point 1). Finally, we have added text about the benefits and limitations of the T:T presentation system, as well as how our in vitro results might relate to in vivo T cell differentiation:

Results: "In contrast to this reductionist system, many additional factors impact T cell activation in vivo. Most fundamentally, naïve T cells are activated in the lymph node by professional antigen-presenting cells (APCs), such as dendritic cells, instead of other T cells. These APCs express costimulatory ligands in addition to peptide-MHC complexes, which can further tune naïve T cell responses (L. Chen and Flies, 2013; Hubo et al., 2013)."

Discussion: "... this in vitro system is nevertheless still far-removed from in vivo T cell activation, where the microenvironment is increasingly complex. \[...\] By delineating the impact of stimulation strength in low-complexity systems, these data can form the basis for interpretation of future studies where additional variables may be explored."

> 4\) With only two biological replicates there is a question of statistical significance of the observations. Can the authors comment on the reproducibility of the mass cytometry experiment? Is there a way to attach a statistical likelihood to the possibility that the signaling trajectories are actually different for the different ligands, but this has been missed due to variability of the data and the limited number of replicates? This is an interesting cased where there is a lot of very detailed data from only two observations (plus additional flow cytometry data sets) and there is effectively only one technical replicate as I believe the two biological replicates were run at the same time on the machine with bar coding to distinguish them. Some discussion of how statistical assessment of the conclusion can be made would be very helpful.

We apologise for any confusion about the number of replicates included in mass cytometry experiments and lack of clarity about statistical analyses. Six biological replicates were examined by mass cytometry, although not all had data for all time points. We have added tables delineating the replicate structure and statistics for replicate measurements of individual signalling molecules and multidimensional phenotypes (new Supplementary files 1 and 5).

We have also added an expanded description of the cydar method for mass cytometry differential abundance analysis:

"To test for differential abundance of cells with any combinatorial phenotype, agnostic to cellular density or clustering patterns, we employed cytometry differential abundance testing in R (cydar, (A. T. L. Lun et al., 2017)). This method takes advantage of the consistent staining achieved with sample barcoding, along with the count-based nature of single cell data, to find regions of the high-dimensional marker space occupied significantly more or less frequently by cells from a particular condition. This is achieved by filling the marker space with hyperspheres, comparing cellular abundances within each hypersphere across conditions, and controlling the false discovery rate across the marker space."

We used cydar to test for differentially abundant populations between any stimulation condition and unstimulated controls. Due to cydar's cluster-free approach, drift in the mass cytometry detector between tubes can falsely appear as differential abundance of subtly different cellular phenotypes. For this reason, only experiments that are directly multiplexed or include a subset of shared samples that can be used for normalization are compatible with this method (Lun ATL et al., 2017). Therefore, cydar statistical tests were run on a mass cytometry experiment comprised of 2 biological replicates of the full time-course with a strategically multiplexed design that maximized the number of samples that could be included within the 20 mass cytometry barcodes available from Fluidigm (as detailed in Supplementary file 1). All reported differentially abundant phenotypes met statistical significance using a false discovery rate threshold of 5 %. Using phenotypes identified by this differential abundance analysis (Figure 4A), we then specifically gated this mass cytometry experiment (2 biological replicates) and a second experiment (4 biological replicates at overlapping time points) to generate the kinetics plots of the various phenotypes observed and confirm their reproducibility across more replicates (Figure 4B-C, statistics provided in new Supplementary file 5). Additional replication of certain markers was provided by flow cytometry analyses throughout the manuscript.

We appreciate the reviewer's request for a statistical assessment of the likelihood that signalling trajectories are shared across stimuli. We have now plotted the inferred trajectories of activation events described in Figure 5 (pS6, pERK, pSTAT5, CD44) for cells stimulated with each ligand (new Figure 5---figure supplement 1A-C). We also added an explicit test of the probability that the order of activation events occurring after stimulation with each ligand would be as similar as observed if all events occurred at random. These analyses are described in the text (Materials and methods and Results) as follows:

Materials and methods: "For trajectory analysis, each biological replicate was analysed separately. A logicle transformation (default parameters except w=0.1) was applied to raw intensity data. \[...\] It was not possible to order events in the remaining biological replicates from experiment 1 that included only 1 stimulated timepoint."

Results: "To formally test this order of activation events, we constructed activation trajectories of cells under each stimulation condition across all time points, based on their expression of pS6 (Figure 5---figure supplement 1A). \[...\] The signalling molecules pAKT, pLCK and IκBα were less dynamic along the trajectory, precluding precise determination of their order of activation particularly in weakly stimulated cells, but visualizing their changes along the trajectory further suggested shared patterns between stimuli (Figure 5---figure supplement 1D)."

> Reviewer \#2:
>
> \[...\] The manuscript powerfully illustrates the potential of mass cytometry to unravel complex mechanisms in T cell signalling. However, a modest scale and a few experimental constraints substantially limit the actual insight gained into T cell activation.
>
> In this manuscript, naïve T cells are activated by presenting peptide to each other. I appreciate that this allows for the unambiguous assignment of mass cytometry signals to the T cells. It also forces T cells to activate with limited availability of costimulation. This may explain why there is virtually no activation of four (fairly proximal) of the nine signalling intermediates assayed, ZAP-70, SLP-76, PLCgamma and Akt. There are no changes in Lck phosphorylation (consistent with Acuto lab data) and CD25 expression. Thus the nine signalling intermediate panel essentially contracts to four signalling intermediates, Erk, STAT5, S6 and IκB. This removes a key strength of mass cytometry from this study, the ability to determine relations between significant changes across numerous events. Some signalling intermediates are preferentially expressed in T cells, e.g. LAT and SLP-76. They, therefore, could be unambiguously detected in T cells activated more efficiently by professional APCs such as dendritic cells. In addition, as mass cytometry is a single cell approach, T cells could be dissociated from activating APCs before processing for mass cytometry and T cell-specific events identified with antibodies against T cell surface markers, such as the TCR or CD8. Even though a complete study using professional APCs such as DCs would be well beyond the scope of any revision, any insight from pilot experiments whether such APCs could trigger more effective signalling that can be unambiguously be assigned to the T cells would be of great use for other investigators planning to use mass cytometry to investigate T cell signalling.

We agree that examination of signalling after stimulation with professional antigen presenting cells is of great interest. We have now activated naïve T cells with peptide-pulsed BMDCs and examined their signalling at selected proximal and distal signalling nodes (pZAP70, pSLP76, pERK1/2, pS6, pSTAT5), as well as CD44 expression, by flow cytometry (new Figure 7). These data showed that pSLP76, pERK1/2 and CD44 responded in potency-dependent manners similar to T-cell-T-cell antigen presentation, while pS6 was upregulated with high, medium and low potency stimuli in a potency-independent manner, and pSTAT5 was activated simply by co-culture with BMDCs. These results are described and discussed in the text (Results and Discussion) as follows:

Results: "To test how signalling responses to ligands of different strengths might be impacted by the additional signalling conferred by professional APCs, we stimulated naïve T cells with mature BMDCs (Figure 7---figure supplement 1B-C) loaded with peptides of various potencies. \[...\] These results indicate that the rate-based mechanism we observed in the T:T stimulation system is further tuned at particular signalling nodes by more complex antigen presentation."

Discussion: "Under stimulation with peptide-loaded BMDCs, ligand potency determined the percentages of T cells undergoing certain activation events (pERK1/2, pSLP76 and CD44), similar to observations in our reductionist stimulation system. \[...\] Further exploration of how individual costimulatory ligands impact the coordination and initiation rate of the TCR-induced signalling programme will be important for dissecting these additional inputs."

> The authors decided to supply exogenous IL-2. As IL-2 provides auto/paracrine amplification of T cell activation this likely has led to less variable data sets. However, increased distinction between T cell activation conditions provided by such amplification could have also provided additional physiological insight into mechanisms of T cell signal discrimination. Again, some initial insight from pilot studies that would extend the determination of the role of exogenous IL-2 from STAT5 and SP6 to other signalling intermediates could be of great value to other investigators.

We have now examined the impact of IL2 on pAKT, pERK and IκBα signalling (newly expanded Figure 3---figure supplement 2B) and have found no impact of IL2 on signalling at pERK or IκBα, and a subtle effect on pAKT in our stimulation conditions. These results are described in the text as follows:

"The percentages of cells degrading IκBα or phosphorylating S6 or ERK1/2 were not impacted by the presence of exogenous IL2. The percentages of cells phosphorylating pAKT\[S473\] were subtly increased by IL2 particularly under stimulation with low potency ligands (Figure 3---figure supplement 2B). This may reflect the mechanism proposed by Ross et al. whereby JAK signalling induced by IL2 ultimately stimulates mTORC2 phosphorylation of AKT\[S473\] (Ross et al., 2016)."

> One of the key challenges in T cell signalling is to connect signalling on the time scale of minutes to hours to cell fate on the time scale of days. While there is plenty of data in general on the response of naïve OT-I T cells to the peptide variants used , e.g. in the induction of proliferation, cytokine secretion and cytolytic capability, it would be good if such data directly related to the specific naïve T cell activation conditions used here, i.e. peptide presentation between naïve T cells. This is of particular interest as signalling differences at the last, 6-hour, time point in response to the different peptides are surprisingly small (as beautifully summarised in Figure 4---figure supplement 2 and also apparent in Figure 6B). This raises important questions. With signalling differences at 6 hours that small, what are the consequences for presumably substantially divergent later activation events? If later differences are more closely related to signalling at 2 to 4 hours, how are such differences "remembered"? Do we need to find additional signalling events to effectively link signalling on the time scale of hours to consequences on the time scale of days? Thus, knowing standard T cell activation outcomes in response to the different peptides under the specific experimental T cell activation conditions used in this study would be very useful.

We thank the reviewer for highlighting this point of interest. The in vitro T cell activation system we use in the presence of exogenous IL-2 promotes effector differentiation, as described in our response to reviewer 1, point 3. We previously conducted a study using this activation system in which we profiled mRNA expression after 6 hours, and CD44 protein expression and proliferation after 2 days (Richard et al., 2018). These data demonstrated that, regardless of stimulation strength, T cells followed the same main transcriptional activation pathways and were capable of proliferation and CD44 expression. Instead, stimulation strength altered the probability that a given cell would initiate transcriptional activation. We have expanded the text to describe these outcomes as follows:

"Using this reductionist stimulation system, we previously found that stimulation strength determined the rate with which naïve T cells initiated transcriptional activation but that cells activated by all ovalbumin-derived ligands were proliferating and expressing the effector molecule CD44 by two days (Richard et al., 2018)."

> In summary, the manuscript powerfully illustrates how much and interesting data can in principle be generated by applying mass cytometry approaches to T cell activation. In its current form, however, physiological insight remains limited by the small effective size of the antibody panel (only three discriminatory markers), the choice of T cell activation without APC and upon addition of exogenous IL-2 and the lack of direct relation to long-term outcomes of T cell signalling under the chosen experimental conditions. An expansion of the antibody panel is certainly beyond the scope of any reasonable revision. However, pilot experiments to illustrate consequences of the experimental choices together with a determination of long-term T cell activation consequences and an acknowledgement of limitations in physiological insight caused by the small effective antibody panel could still make this an influential manuscript for future work on unravelling T cell signalling complexity with mass cytometry.

We appreciate that the reviewer sees the potential of mass cytometry to address questions of T cell signalling and fully acknowledge that our study is limited in the number of dynamic markers tested. We believe that the use of a minimal in vitro system adding pure peptide in the presence of IL2 allowed us to examine the impact of stimulation strength on *cell-intrinsic* signalling processes without contributions from costimulation or autocrine/paracrine IL2 feedback. Understanding these effects can then facilitate more nuanced interpretation of increasingly complex systems. In addition to adding experiments that begin to extend these findings (including additional signalling events profiled in the absence of IL2 and after stimulation with peptide-pulsed BMDCs), we have also added discussion of the rationale and limitations of our stimulation system and how results may differ in more physiological settings as described in response to reviewer 1 point 3.

> Reviewer \#3:
>
> This is in principle a highly relevant and in key parts still barely understood matter. However, I have several issues with the manuscript of which the key points are i) lack of novelty and ii) that only circumstantial evidence is presented.
>
> I see only incremental new insights that in my opinion do not move the field forward or provide real answers. Moreover, the authors want to put the message forward that mainly kinetic difference and not the signals quality determine the outcome of high versus low affinity signaling. While this is an interesting hypothesis, the authors present only circumstantial evidence and do not establish a causal relationship.

While we agree that the insights we were able to gather from our study were limited by the number of detectable dynamic markers, we believe that this information is nonetheless valuable to share across the field so that future efforts can build upon our experimental set-up and results as described in response to reviewer 1 point 3.

In light of the limited number of dynamic signalling molecules we profiled in the current study and to address the possibility that other unmeasured signalling events do not respond to different strengths of stimulation with altered activation rates, we have also added appropriate caveats to our conclusions in the text (Abstract, Introduction and Discussion):

Abstract: "Using mass cytometry to simultaneously measure multiple signalling pathways, we found a programme of distal signalling events that is shared, regardless of the strength of TCR stimulation."

Introduction: "Our data suggest that the coordination of the TCR-induced signalling pathways that we tested does not vary with stimulation strength."

Discussion: "In this study, we measured 22 markers of protein expression and active signalling. While other unmeasured signalling mediators may respond to altered stimulation strength in a different manner, our data demonstrate a strict choreography of the distal signalling processes that we examined."

With respect to how the observed kinetic differences in signalling might relate to the ultimate outcomes of high versus low potency signalling, particularly in a physiological setting, we have modified the text as described in response to reviewer 1 point 3 and reviewer 2 points 3 and 4.

> Other issues involve that the authors mainly use a fixed concentration of peptide which is with 1uM quite high, while titration experiments are rare. Moreover, would the same signaling pattern be observed when the cells are exposed to the same ligands in vivo?

The goal of our study was to examine the impact of stimulation strength. We therefore sought to saturate the antigen presentation and response machinery to limit the influence of concentration-dependent differences. We previously found that a 1 μM concentration of these peptides saturated changes in surface protein expression after 4 hours of stimulation (Richard et al., 2018), and in the current manuscript we demonstrated the same for pERK and pS6 signalling at 2 and 4 hours (Figure 2---figure supplement 1).

Regarding how our in vitro system would compare to in vivo responses, please see the response to reviewer 1 point 3 and reviewer 2 point 4.

\[Editors' note: what follows is the authors' response to the second round of review.\]

> The reviewers and editors nonetheless suggest essential revision to address the potential of pErk1/2 to encode information about the different ligands that may not be fully read out in your otherwise thorough analysis. One effect that stands out in the data appears to be an affinity-related all-or- none involvement of the ERK pathway. Activation or lack of activation of pERK distinguishes two clusters of otherwise-coordinate responses, and while this pERK activation is frequent and early in cells activated by high-affinity ligands, it is hardly detectable at all in cells activated with low-affinity ligands, even at later time-points when all the other pathways have become activated. The fact that all the other pathways tested show kinetic but not qualitative differences in response to high and low affinity ligands makes the distinctive behavior of ERK very interesting.
>
> You state that: \"Given that we found full S6 phosphorylation requires MEK signalling, we hypothesize that transient ERK activation events (Ryu et al., 2018) occurred in many cells outside of the snapshots of our measurements.\" You assume that if you used a \"real-time\" reporter that G4 would cause pErk1/2 to \"blink\" at a frequency sufficient to account for the Mek contribution of pS6, but very rarely captured in the snapshot? It might be helpful to be more explicit about this or even make this prediction if it's how you account for the result. It seems that what we know about pErk activation could fit with this and in addition to Ryo et al. it might make sense to cite Huang WYC, Alvarez S, Kondo Y, Lee YK, Chung JK, Lam HYM, Biswas KH, Kuriyan J, Groves JT. A molecular assembly phase transition and kinetic proofreading modulate Ras activation by SOS. Science. 2019;363(6431):1098-103. Epub 2019/03/09. doi: 10.1126/science.aau5721. PubMed PMID: 30846600; PMCID: PMC6563836 as it makes a case for how Erk activation down stream of Sos could have this property.

We agree with the reviewer's interpretation of our hypothesized mechanism and thank the reviewer for calling our attention to the relevant paper by Huang et al. We have revised the Discussion as follows to clarify our hypothesis and incorporate additional references:

"Given that we found full S6 phosphorylation after strong stimulation requires MEK signalling, we hypothesize that this pathway is active in all stimulation conditions but that ERK activation events occur with reduced frequency or duration with weak stimuli and thus many were missed in our snapshot measurements. \[...\] Such an effect on digital ERK activation may be modulated by multi-step activation of the upstream mediator SOS dependent on its dwell-time after activation-induced recruitment to the plasma membrane (Huang et al., 2019)."

> Is it possible that even though this blinking is sufficient for pS6, that perhaps other TF like Elk might decode this differently and allow qualitatively different responses to these ligands?

This is an important point, and we have added the following to the Discussion:

"Interestingly, using a light-inducible ERK activation system in epithelial cells, Aoki et al. demonstrated divergent transcriptional effects of sustained versus transient ERK activation (Aoki et al., 2013). It therefore remains possible that different ERK targets in T cells, such as translational machinery, microtubule remodelling, and transcription factors (e.g. ELK1, SAP1, SAP2) (Navarro and Cantrell, 2014) are differentially affected by stimulation strength, warranting further investigation of additional downstream components."

> While the Erk1/2 signal may be showing such blinking, this is not demonstrated here and the pS6 phosphorylation could be driven by other signals than Erk1/2.

Although we found in Figure 3 that under N4 stimulation, the percentage of cells phosphorylating S6 \[S235/S236\] was reduced MEK162 treatment, we agree that it remains possible that this mechanism is not the same under G4 stimulation. We have therefore added a call for future investigation of this prediction as described in point (A).

> Figure 5 is actually misleading in the absence of direct evidence for the pErk in the G4 cells.

Figure 5 reflects the kinetics we observed in Figures 3 and 4 where the percentages of cells exhibiting the phenotypes (ie the direct evidence) are provided. We have expanded the legend to Figure 5 to clarify this point:

"Cartoon depicts the kinetics of the 4 main signalling phenotypes in cells stimulated with ligands of varying potencies (N4, T4, G4) over time from data in Figures 3A and 4A-B (note the transient pERK^+^ populations, even with G4). Black outlines indicate CD44+ populations."

> This requires a more critical discussion as it's not clear you have proven that the cell will ignore the information encoded in the pERK1/2 node even if your untested working model is correct.

The Discussion has been modified as described in the response above.

[^1]: These authors contributed equally to this work.
